Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 11

Clinical outcomes and risk factors associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria in hospitalized patients: a prospective cohort study in Libya Open Access

Abstract

Bloodstream infections (BSIs) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) are a major cause of mortality, with limited treatment options.

Despite the global rise of MDR-GNB, prospective data on their clinical impact in North Africa remain scarce, restricting evidence-based guidance for empiric therapy.

To assess the prevalence, resistance patterns and clinical outcomes of MDR-GNB BSIs in Libya, and to identify predictors of 30-day mortality.

A prospective cohort study was conducted in two Libyan hospitals between November 2022 and November 2024. Adult patients with positive blood cultures were enrolled. Isolates were identified using standard microbiological methods, and antimicrobial susceptibility testing was interpreted according to Clinical and Laboratory Standards Institute (CLSI) 2023 guidelines. Multivariable logistic regression was applied to identify independent predictors of 30-day mortality.

Among 673 BSI episodes, 37.4% were multidrug resistance (MDR). (32.0%) and (25.9%) predominated, while carbapenem resistance was highest in (42.4%). Overall, 30-day mortality was 23.8%, and was significantly higher in MDR infections (32.1% vs 18.8%; <0.001). Independent predictors of mortality were MDR infection [adjusted odds ratio (aOR), 1.9], Intensive care Unit (ICU) admission (aOR, 2.6), Charlson Comorbidity Index ≥3 (aOR, 1.7) and inappropriate empiric therapy (aOR, 2.3).

MDR-GNB BSIs are highly prevalent in Libya and substantially worsen outcomes. These findings highlight the urgent need for improved empiric therapy, antimicrobial stewardship and infection control programmes.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antimicrobial stewardship , bloodstream infection (BSI) , Gram-negative bacteria , Libya , mortality and multidrug resistance (MDR)
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.002101
2025-11-27
2025-12-15

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/11/jmm002101.html?itemId=/content/journal/jmm/10.1099/jmm.0.002101&mimeType=html&fmt=ahah

References

  1. Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med 2023; 49:178–190 [View Article]
     [Google Scholar]
  2. Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet 2025; 405:257–272 [View Article] [PubMed]
     [Google Scholar]
  3. Waele JJ, Akova M, Antonelli M, Bassetti M, Kollef M et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. Intensive Care Med 2018; 44:189–196 [View Article]
     [Google Scholar]
  4. Deku JG, Bedzina I, Amankwah PK, Antor LK, Ablordey K et al. Emerging antibiotic resistance in bacterial bloodstream infections: a clinical study at the Holy Family Hospital, Nkawkaw, Ghana. BMC Infect Dis 2025; 25:721 [View Article] [PubMed]
     [Google Scholar]
  5. Cornistein W, Balasini C, Nuccetelli Y, Rodriguez VM, Cudmani N et al. Prevalence and associated mortality of infections by multidrug-resistant organisms in pediatric intensive care Units in Argentina (PREV-AR-P). Antibiotics 2025; 14:493 [View Article] [PubMed]
     [Google Scholar]
  6. Dicharry D, Smith DG, Khan MH, Self M, Parikh C et al. Clinical features of multidrug-resistant gram-negative bacteremia: a comparative study of cancer and non-cancer patients. Microorganisms 2025; 13:2110 [View Article] [PubMed]
     [Google Scholar]
  7. Daw MA, Mahamat MH, Wareg SE, El-Bouzedi AH, Ahmed MO. Epidemiological manifestations and impact of healthcare-associated infections in Libyan national hospitals. Antimicrob Resist Infect Control 2023; 12:122 [View Article] [PubMed]
     [Google Scholar]
  8. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing. 33rd Ed. CLSI Supplement M100 Wayne, PA: CLSI; 2023
     [Google Scholar]
  9. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum -lactamases conferring transferable resistance to newer -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Clin Infect Dis 1988; 10:867–878 [View Article]
     [Google Scholar]
  10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657–686 [View Article] [PubMed]
     [Google Scholar]
  11. Zwaluw K, Haan A, Pluister GN, Bootsma HJ et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the carba NP test. PLoS One 2015; 10:e0123690 [View Article]
     [Google Scholar]
  12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: interim standard definitions. Clin Microbiol Infect 2012; 18:268–281 [View Article]
     [Google Scholar]
  13. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589–1596 [View Article] [PubMed]
     [Google Scholar]
  14. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:762–774 [View Article] [PubMed]
     [Google Scholar]
  15. Alhubail MA, Elmuneef N, Alkhumra H, Balkhy HH, Al-Qahtani A et al. Prevalence and outcomes of gram-negative bloodstream infections in hospitalized patients: a multicenter study from Saudi Arabia. J Infect Public Health 2024; 17:928–935 [View Article]
     [Google Scholar]
  16. Azzam A, El-Kholy A, El-Mahallawy H, Abdelrahman N, El-Korashy R et al. Prevalence and molecular characterization of ESBL-producing enterobacterales in Egypt: a systematic review. Infect Drug Resist 2024; 17:1859–1874 [View Article]
     [Google Scholar]
  17. Kanzari L, Ben Rejeb H, Ouzari H, El-Bouja A, Ben Ahmed H et al. Bacterial pathogens and antibiotic resistance in bloodstream infections in Tunisia: a 13-year trend analysis. Pathogens 2025; 14:511 [View Article]
     [Google Scholar]
  18. Lyazidi S, El Marnissi B, El Hadef R, Oumokhtar B, El Kettani A. Prevalence of healthcare-associated infections in a Moroccan tertiary hospital: ICU burden and pathogen profile. Infect Drug Resist 2024; 17:2123–2134 [View Article]
     [Google Scholar]
  19. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012; 16:S27–S36 [View Article]
     [Google Scholar]
  20. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41:281–288 [View Article]
     [Google Scholar]
  21. Rottier WC, Bamberg YR, Dorigo-Zetsma JW, Linden PD, Bonten MJM et al. Predictors of multidrug-resistant gram-negative bacteremia: a systematic review. Clin Microbiol Infect 2021; 27:530–537 [View Article]
     [Google Scholar]
  22. Şimşek Bozok T, Bozok T, Şahinoğlu MS, Kaya H, Horasan EŞ et al. Bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae: analysis of risk factors, treatment responses and mortality. Infect Dis 2025; 57:350–360 [View Article] [PubMed]
     [Google Scholar]
  23. Liao CH, Chen SY, Chang SC, Hsueh PR, Wang JL et al. Risk factors for bloodstream infections caused by multidrug-resistant gram-negative bacteria in Asia: a multicenter study. J Infect 2020; 81:702–709 [View Article]
     [Google Scholar]
  24. Allel K, Karmakar M, Abdelhamid YA, Patel A, Raina M et al. Impact of inappropriate empirical antibiotic therapy on in-hospital mortality: systematic review and meta-analysis. BMJ Public Health 2024; 2:e001289 [View Article]
     [Google Scholar]
  25. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 2003; 5:449–456 [View Article] [PubMed]
     [Google Scholar]
  26. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538–582 [View Article] [PubMed]
     [Google Scholar]
  27. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother 2017; 72:2145–2155 [View Article] [PubMed]
     [Google Scholar]
  28. Charfi-Kessis K, Mansour W, Ben Haj Khalifa A, Gharbi A, Messaoudi A et al. High prevalence of ESBL-producing klebsiella pneumoniae in north Africa: molecular insights. Infect Genet Evol 2014; 27:336–341 [View Article]
     [Google Scholar]
  29. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017; 215:S28–S36 [View Article] [PubMed]
     [Google Scholar]
  30. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 2017; 17:153–163 [View Article] [PubMed]
     [Google Scholar]
  31. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B et al. Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev 2017; 30:409–447 [View Article]
     [Google Scholar]
  32. Horcajada JP, Montero M, Oliver A, Sorli L, Luque S et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32:e00031–19 [View Article]
     [Google Scholar]
  33. World Health Organization (WHO) Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2024 Geneva: WHO; 2024
     [Google Scholar]
  34. European Centre for Disease Prevention and Control (ECDC) Surveillance of antimicrobial resistance in Europe 2023: Annual report. Stockholm: ECDC; 2024
  35. Canton R, Gonzalez-Alba JM, Galan JC. CTX-m enzymes: origin and diffusion. Front Microbiol 2012; 3:110 [View Article]
     [Google Scholar]
  36. Storberg V. ESBL-producing Enterobacteriaceae: resistance mechanisms, epidemiology and clinical implications. Infect Ecol Epidemiol 2014; 4:22924 [View Article]
     [Google Scholar]
  37. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–327 [View Article] [PubMed]
     [Google Scholar]
  38. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791–1798 [View Article] [PubMed]
     [Google Scholar]
  39. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom 2019; 5:e000306 [View Article] [PubMed]
     [Google Scholar]
  40. Higgins PG, Perez-Llarena FJ, Zander E, Fernandez A, Bou G et al. Epidemiology and resistance mechanisms of global acinetobacter baumannii isolates: outbreak investigations. J Hosp Infect 2010; 74:327–337 [View Article]
     [Google Scholar]
  41. Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159–166 [View Article] [PubMed]
     [Google Scholar]
  42. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13:151–171 [View Article] [PubMed]
     [Google Scholar]
  43. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16:161–168 [View Article] [PubMed]
     [Google Scholar]
  44. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 2017; 30:557–596 [View Article] [PubMed]
     [Google Scholar]
  45. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22:664–689 [View Article] [PubMed]
     [Google Scholar]
  46. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943–950 [View Article] [PubMed]
     [Google Scholar]
  47. Kumar A, Ellis P, Arabi Y, Roberts D, Light B et al. Initiation of inappropriate antimicrobial therapy results in fivefold reduction of survival in human septic shock. Crit Care Med 2009; 37:273–280 [View Article]
     [Google Scholar]
  48. Kollef MH, Zilberberg MD, Shorr AF, Micek ST, Mody SH et al. Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect 2011; 62:130–135 [View Article]
     [Google Scholar]
  49. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383 [View Article] [PubMed]
     [Google Scholar]
  50. Al-Otaibi FE, Bukhari EE. Clinical and microbiological characteristics of bloodstream infections caused by multidrug-resistant gram-negative bacteria in a tertiary care hospital in Saudi Arabia. Saudi Med J 2020; 41:733–739 [View Article]
     [Google Scholar]
  51. Ben Amor Z, Oueslati S, Ben Lakhal R, Hammami S, Achour W et al. Healthcare costs and outcomes of multidrug-resistant gram-negative bloodstream infections in Tunisia: a matched cohort study. J Glob Antimicrob Resist 2021; 24:312–318 [View Article]
     [Google Scholar]
  52. Kadri SS, Lai YL, Rhee C, Strich JR, Murphy DJ. Inappropriate empirical antibiotic therapy for bloodstream infections: prevalence and effect on mortality. Open Forum Infect Dis 2021; 8:fab196 [View Article]
     [Google Scholar]
  53. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 2022; 399:629–655 [View Article]
     [Google Scholar]
  54. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913–920 [View Article] [PubMed]
     [Google Scholar]
  55. Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49:1175–1184 [View Article] [PubMed]
     [Google Scholar]
  56. Allegranzi B, Tartari E, Pittet D. Preventing healthcare-associated infections: global progress and challenges. Curr Opin Infect Dis 2021; 34:327–336 [View Article]
     [Google Scholar]
  57. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum β-lactamase, ampc, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev 2018; 31:e00079–17 [View Article]
     [Google Scholar]
  58. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis 2017; 64:15–23 [View Article]
     [Google Scholar]
  59. Mendelson M, Matsoso MP. The world health organization global action plan on antimicrobial resistance: progress and opportunities. Lancet Infect Dis 2015; 15:1357–1359 [View Article]
     [Google Scholar]
  60. Hsueh PR, Paterson DL. Multidrug-resistant gram-negative bacteria in Asia: epidemiology and treatment options. Curr Opin Infect Dis 2020; 33:125–135 [View Article]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.002101
Loading
Clinical outcomes and risk factors associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria in hospitalized patients: a prospective cohort study in Libya
J. Med. Microbiol. 74, 002101 (2025); https://doi.org/10.1099/jmm.0.002101
/content/journal/jmm/10.1099/jmm.0.002101
/content/journal/jmm/10.1099/jmm.0.002101
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error